These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37651021)

  • 21. Prognosis of microsatellite instability and/or mismatch repair deficiency stage III colon cancer patients after disease recurrence following adjuvant treatment: results of an ACCENT pooled analysis of seven studies.
    Taieb J; Shi Q; Pederson L; Alberts S; Wolmark N; Van Cutsem E; de Gramont A; Kerr R; Grothey A; Lonardi S; Yoshino T; Yothers G; Sinicrope FA; Zaanan A; André T
    Ann Oncol; 2019 Sep; 30(9):1466-1471. PubMed ID: 31268130
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic value of Lynch syndrome, BRAF
    Zwart K; van der Baan FH; Cohen R; Aparicio T; de la Fouchardiére C; Lecomte T; Punt CJA; Sefrioui D; Verheijden RJ; Vink GR; Wensink GE; Zaanan A; Koopman M; Tougeron D; Roodhart JML
    Cancer Med; 2023 Aug; 12(15):15841-15853. PubMed ID: 37326121
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment patterns and real-world clinical outcomes in patients with advanced endometrial cancer who are microsatellite instability (MSI)-high or are mismatch repair deficient (dMMR) in the United States.
    Kelkar SS; Prabhu VS; Corman S; Odak S; Rusibamayila N; Macahilig C; Orlowski R; Duska L
    Gynecol Oncol; 2023 Feb; 169():154-163. PubMed ID: 36344294
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Micro Satellite Instability and Mismatch Repair Status in Different Solid Tumors: A Multicenter Analysis in a Real World Setting.
    Malapelle U; Parente P; Pepe F; De Luca C; Pisapia P; Sgariglia R; Nacchio M; Gragnano G; Russo G; Conticelli F; Bellevicine C; Vigliar E; Iaccarino A; Covelli C; Balistreri M; Clemente C; Perrone G; Danza A; Scaramuzzi F; Fassan M; Troncone G; Graziano P
    Cells; 2021 Jul; 10(8):. PubMed ID: 34440647
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour mutational burden as a biomarker in patients with mismatch repair deficient/microsatellite instability-high metastatic colorectal cancer treated with immune checkpoint inhibitors.
    Manca P; Corti F; Intini R; Mazzoli G; Miceli R; Germani MM; Bergamo F; Ambrosini M; Cristarella E; Cerantola R; Boccaccio C; Ricagno G; Ghelardi F; Randon G; Leoncini G; Milione M; Fassan M; Cremolini C; Lonardi S; Pietrantonio F
    Eur J Cancer; 2023 Jul; 187():15-24. PubMed ID: 37099945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating mismatch repair deficiency for solid tumor immunotherapy eligibility: immunohistochemistry versus microsatellite molecular testing.
    Saeed OAM; Mann SA; Luchini C; Huang K; Zhang S; Sen JD; Piredda ML; Wang M; Baldrige LA; Sperling RM; Curless KL; Cheng L
    Hum Pathol; 2021 Sep; 115():10-18. PubMed ID: 34052294
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Complete Pathological Response After Neoadjuvant Short-Course Immunotherapy with Ipilimumab and Nivolumab in Locally Advanced MSI-H/dMMR Rectal Cancer.
    Trojan J; Stintzing S; Haase O; Koch C; Ziegler P; Demes M; Jelas I
    Oncologist; 2021 Dec; 26(12):e2110-e2114. PubMed ID: 34431576
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Relationship of microsatellite instability to mismatch repair deficiency in malignant tumors of dogs.
    Inanaga S; Igase M; Sakai Y; Hagimori K; Sunahara H; Horikirizono H; Itamoto K; Baba K; Ohsato Y; Mizuno T
    J Vet Intern Med; 2022 Sep; 36(5):1760-1769. PubMed ID: 35959511
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness of pembrolizumab for the first-line treatment of patients with unresectable or metastatic MSI-H/dMMR colorectal cancer in the United States.
    Aguiar-Ibáñez R; Hardern C; van Hees F; Lee D; Patel A; Chhabra N; Baluni G; Amonkar M; Lai Y; Xu R; Massaad R; Fogelman D
    J Med Econ; 2022; 25(1):469-480. PubMed ID: 35184650
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant Immunotherapy With Ipilimumab Plus Nivolumab in Mismatch Repair Deficient/Microsatellite Instability-High Colorectal Cancer: A Preliminary Report of Case Series.
    Pan T; Yang H; Wang WY; Rui YY; Deng ZJ; Chen YC; Liu C; Hu H
    Clin Colorectal Cancer; 2024 Mar; 23(1):104-110. PubMed ID: 38336555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunotherapy in mismatch repair-deficient metastatic colorectal cancer - Outcome and novel predictive markers.
    Stemmer A; Margalit O; Serpas V; Strauss G; Thomas J; Shah P; Tau N; Levanon K; Shacham-Shmueli E; Kopetz S; Overman M; Boursi B
    Eur J Cancer; 2024 Feb; 198():113495. PubMed ID: 38157568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Single-cell sequencing reveals the immune microenvironment landscape related to anti-PD-1 resistance in metastatic colorectal cancer with high microsatellite instability.
    Wu T; Zhang X; Liu X; Cai X; Shen T; Pan D; Liang R; Ding R; Hu R; Dong J; Li F; Li J; Xie L; Wang C; Geng S; Yang Z; Xing L; Li Y
    BMC Med; 2023 Apr; 21(1):161. PubMed ID: 37106440
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to Chemotherapy and Prognosis in Metastatic Colorectal Cancer With DNA Deficient Mismatch Repair.
    Alex AK; Siqueira S; Coudry R; Santos J; Alves M; Hoff PM; Riechelmann RP
    Clin Colorectal Cancer; 2017 Sep; 16(3):228-239. PubMed ID: 28063788
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association Between Survival and Metastatic Site in Mismatch Repair-Deficient Metastatic Colorectal Cancer Treated With First-line Pembrolizumab.
    Saberzadeh-Ardestani B; Jones JC; Hubbard JM; McWilliams RR; Halfdanarson TR; Shi Q; Sonbol MB; Ticku J; Jin Z; Sinicrope FA
    JAMA Netw Open; 2023 Feb; 6(2):e230400. PubMed ID: 36811859
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer.
    Oh CR; Kim JE; Hong YS; Kim SY; Ahn JB; Baek JY; Lee MA; Kang MJ; Cho SH; Beom SH; Kim TW
    Int J Cancer; 2022 Jun; 150(12):2038-2045. PubMed ID: 35179785
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Is Adjuvant Chemotherapy Necessary for Patients with Deficient Mismatch Repair Gastric Cancer?-Autophagy Inhibition Matches the Mismatched.
    Tsai CY; Lin TA; Huang SC; Hsu JT; Yeh CN; Chen TC; Chiu CT; Chen JS; Yeh TS
    Oncologist; 2020 Jul; 25(7):e1021-e1030. PubMed ID: 32058649
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant Chemotherapy for Gastric Cancer Patients with Mismatch Repair Deficiency or Microsatellite Instability: Systematic Review and Meta-Analysis.
    Nie RC; Chen GM; Yuan SQ; Kim JW; Zhou J; Nie M; Feng CY; Chen YB; Chen S; Zhou ZW; Wang Y; Li YF
    Ann Surg Oncol; 2022 Apr; 29(4):2324-2331. PubMed ID: 34796431
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A TGFβ-Dependent Stromal Subset Underlies Immune Checkpoint Inhibitor Efficacy in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Colorectal Cancer.
    Endo E; Okayama H; Saito K; Nakajima S; Yamada L; Ujiie D; Kase K; Fujita S; Endo H; Sakamoto W; Saito M; Saze Z; Momma T; Ohki S; Mimura K; Kono K
    Mol Cancer Res; 2020 Sep; 18(9):1402-1413. PubMed ID: 32493700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Characteristics and Outcomes of Treatment in Patients with Stage IV Colorectal Cancer with Mismatch Repair Deficiency].
    Ishibashi K; Chika N; Suzuki O; Ito T; Amano K; Kumamoto K; Fukuchi M; Kumagai Y; Mochiki E; Ishida H
    Gan To Kagaku Ryoho; 2016 Nov; 43(12):1711-1714. PubMed ID: 28133107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heterogeneity of Mismatch Repair Status and Microsatellite Instability between Primary Tumour and Metastasis and Its Implications for Immunotherapy in Colorectal Cancers.
    Evrard C; Messina S; Sefrioui D; Frouin É; Auriault ML; Chautard R; Zaanan A; Jaffrelot M; De La Fouchardière C; Aparicio T; Coriat R; Godet J; Silvain C; Randrian V; Sabourin JC; Guimbaud R; Miquelestorena-Standley E; Lecomte T; Moulin V; Karayan-Tapon L; Tachon G; Tougeron D
    Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35457245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.